Low-level laser therapy (LLLT) delivers red-spectrum light to the scalp through a wearable cap or comb, with the goal of stimulating follicles. The evidence is modest but real — particularly for early-stage loss as an adjunct to other treatments.
LLLT uses red-spectrum light (typically 650–680nm wavelength) delivered through laser diodes or LEDs. The light penetrates the scalp to a depth of about 3–5mm — enough to reach the hair follicle’s bulb — where it’s absorbed by mitochondrial cytochrome oxidase. That triggers a cascade clinicians refer to as “photobiomodulation”: increased ATP production, increased local blood flow, reduced inflammation, and stem-cell activation in the follicular bulge.
The net effect on hair: anagen (growth-phase) duration is extended, miniaturised follicles can re-enlarge if intervention is early enough, and shedding rates drop. The mechanism isn’t fully understood at the molecular level, but the clinical effect has been measurable across multiple small RCTs.
FDA-cleared at-home devices for androgenetic alopecia include the Capillus, iRestore, HairMax, and Theradome caps. Each has slightly different diode counts, wavelength specs, and session-duration requirements, but the underlying mechanism is the same.
The 2013 RCT most often cited (Lanzafame et al.) followed 41 men with androgenetic alopecia using a HairMax LaserComb-equivalent device for 16 weeks. Result: a 39% increase in hair count in the treated group versus sham. Subsequent trials have shown 25–51% more hairs in treated areas, with reported clinical-effectiveness rates above 80% in study populations.
Visible improvement typically begins around 3–6 months of daily use. Density gains plateau by month 12 in most studies. When LLLT is combined with minoxidil or finasteride, the evidence suggests roughly 20–30% additional density benefit over either treatment alone.
Important framing: LLLT maintains and modestly improves existing follicles. It does not regrow hair on completely bald scalp. The expected ceiling is similar to minoxidil monotherapy — useful for early-stage cases, useful as an adjunct, not a substitute for surgical restoration once pattern loss is established.
LLLT works best as an addition to other treatments, not as a substitute for them. For early-stage androgenetic patients, the combination of finasteride + minoxidil + LLLT has stronger evidence than any single therapy alone.
For surgical patients, LLLT can support the recipient area during the early growth phase (months 4–8) and has some evidence for reducing the post-op shed common in months 1–3. We routinely discuss whether a laser cap fits a specific patient’s post-op plan.
For patients who can’t tolerate finasteride (sexual side-effects, post-finasteride concerns, or simple preference), LLLT plus minoxidil is a reasonable combination. Expectations should be modest — visible thickening rather than dramatic regrowth — but it’s a real option for patients who want a non-pharmacological component to their plan.
For women considering medical therapy, LLLT is one of the few options that has FDA clearance for both sexes. For female pattern hair loss, the typical combination is minoxidil + LLLT with optional spironolactone (in consultation with a dermatologist).
Cap (recommended). Daily use at home, 6–30 minutes per session depending on the device. Caps deliver uniform light coverage across the scalp, are easy to use consistently, and the better-built models (Capillus, Theradome, iRestore Elite) hold their performance for years.
Comb. Requires active brushing through the hair for 8–15 minutes per session. Harder to use consistently than a cap, and produces more variable scalp coverage because the user has to manually move it across the scalp. We generally don’t recommend combs over caps unless cost is the deciding factor.
In-clinic high-power hoods. Some clinics offer in-office LLLT delivered through hood-style devices that produce higher per-session light energy than at-home units. They require regular visits (typically twice a week) and are more expensive over time than buying a cap. Most of our patients prefer the at-home cap option for convenience.
FDA clearance matters. The named devices above (Capillus, iRestore, HairMax, Theradome) have FDA clearance specifically for hair growth in androgenetic alopecia. Unbranded units sold cheaply online often do not — and the diode wavelength, output stability, and quality control on those units are unverified. Stick with named, cleared devices.
Side-effect profile. LLLT has essentially no systemic side effects. Reported issues are limited to mild scalp warmth during sessions. There’s no interaction with finasteride or minoxidil, no contraindication for surgical patients, no daily-routine commitment beyond wearing the cap during a TV episode or commute.
Whether LLLT belongs in your treatment plan depends on your stage, your tolerance for daily routines, and what else you’re doing. Send photos for the right framework.